SYGNIS successfully raises 18.3 mn euros through a capital increase

• New funding will accelerate future growth
• Diversification of product pipeline will be advanced

Heidelberg, November 06, 2008 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today announced that it has raised approx. 18.3 mn euros through a capital increase. In total SYGNIS sold 12,694,967 newly issued shares from authorized capital at a price of 1.44 euros and at an exchange ratio of 9:4 to existing shareholders. With the placement of the additional shares, SYGNIS' total registered share capital will increase from 28,563,676.00 euros to 41,258,643.00 euros.

The listing of the new shares on the Frankfurt Stock Exchange is expected to take place by December 2008. As result of the capital increase, the freefloat of the company will decrease on a diluted basis to approx. 42 %, the stake of Bayer AG to approx. 3% and the stake of Dr. Friedrich von Bohlen und Halbach to approx 5%. SYGNIS' largest shareholders dievini Hopp BioTech holding GmbH & Co. KG and BASF SE will increase to approx. 36% and 13%.

On November 12, 2008, the company will publish its half year report of fiscal year 2008/2009.